BioCentury
ARTICLE | Clinical News

FibroGen reports Phase I/II data for pamrevlumab in pancreatic cancer

May 25, 2018 5:03 PM UTC

FibroGen Inc. (NASDAQ:FGEN) reported data from 37 evaluable treatment-naïve patients with locally advanced, unresectable pancreatic cancer in an open-label, U.S. Phase I/II trial showing that pamrevlumab (FG-3019) plus gemcitabine and Abraxane nab-paclitaxel improved the proportion of patients who underwent resection vs. gemcitabine and Abraxane alone (33.3% vs. 7.7%). The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago...